usdaed

And under President Trump, well, the numbers were… enthusiastic. Most presidents get gains, sure. But these were… particularly enthusiastic. A little too enthusiastic, perhaps. So it goes.

Fortunately, amidst all the uncertainty, a few opportunities have surfaced. These aren’t get-rich-quick schemes, mind you. More like solid, dependable vessels navigating a choppy sea. Three consumer discretionary stocks, in particular, strike me as reasonably well-positioned. They aren’t guaranteed winners, of course. Nothing is. But they’re worth a look, if only to remind yourself that even in a world gone slightly mad, some things still hold value.

There is, it appears, a fear lurking beneath the surface of this otherwise buoyant market – a suspicion, perhaps, that present prosperity cannot be indefinitely sustained. This sentiment, whilst rarely articulated with precision, exerts a considerable influence, and renders even the most promising ventures subject to a degree of unwarranted scrutiny. One observes a reluctance to embrace fortune, as if anticipating a subsequent reckoning.

The market, a fickle beast, has begun to question Bitcoin’s supposed virtues. Inflation hedge? A quaint notion, considering its recent performance. A medium of exchange? The rise of stablecoins, tethered to the mundane reality of the U.S. dollar, casts a long shadow. People, it seems, still prefer something they can count, even if it’s merely digits on a screen. And the ETFs? A temporary palliative, a distraction from the underlying anxieties. Precious metals, meanwhile, have ascended to heights that mock Bitcoin’s struggles. The ‘digital gold‘ narrative? A jest, perhaps, told by a desperate court jester.

Two years past, ULA confidently predicted a cadence of twenty to thirty launches annually. The reality, alas, has been a mere four, and even those have not been entirely without incident. One might have hoped that a first attempt, free from the complications of experience, would proceed without fault. And so it did. However, the second launch suffered a most unseemly loss of a nozzle – a circumstance which, whilst not catastrophic, did little to inspire confidence. The third, though nominally successful, was followed by a fourth, wherein the engine exhaust, with a disregard for propriety, proceeded to consume a portion of the booster nozzle itself. One begins to suspect a pattern.

The megacaps, naturally, led the charge. The market, as it so often does, became a pageant of excess, with Nvidia adding a sum exceeding four trillion dollars in market capitalization—a figure that would have made even the most ambitious Roman emperor blush. It was a spectacle, certainly, but one always carries the faint odor of impending disillusionment.

And here’s the kicker. All these supposed ‘genius’ hedge fund managers? Most of them can’t even beat it. Seriously. SPIVA Scorecards say nearly 90% of them underperform the S&P 500 over the last decade. It’s… humiliating, really. Makes you wonder what they’re even doing with all that money. Probably buying yachts. Anyway, John Bogle, the wonderfully sensible founder of Vanguard, had the right idea. He said, “Don’t look for the needle in the haystack. Just buy the haystack.” It’s shockingly straightforward.

Let us begin with a rudimentary exercise in market capitalization. At approximately 61 billion XRP in circulation, with a stated maximum supply of 100 billion, a price of $100 per coin would yield a circulating market capitalization of roughly $6.1 trillion. Accounting for the full potential supply expands this figure to $10 trillion. Such a valuation necessitates comparison to established stores of value.

So, the question isn’t if you should get a slice of this action, but how much sanity you’re willing to sacrifice. Can Domino’s claw its way back to $500? The numbers say maybe. But in this market, “maybe” is a loaded gun pointed at your portfolio. We’re talking about the world’s largest pizza delivery machine, a sprawling empire of dough and desperation. And right now, it feels…vulnerable. But beautifully, dangerously so.

TransMedics offers what they term an “end-to-end” solution, a rather grand phrase for the logistics of keeping a human organ viable outside the human body. Their Organ Care System (OCS), and the accompanying National OCS Program (NOP), aim to replicate, as best they can, the conditions of life. An admirable ambition, though one suspects the organ itself would have little to say on the matter. They possess a network of aircraft and hubs, a considerable undertaking, transporting these fragile hopes across the country. It is a business built on time, on precision, and on the unspoken understanding that every moment lost is a life potentially diminished.